{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-026103","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.220185+00:00","generated_at":"2026-05-26T04:46:44.932184+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cogent Biosciences Q4/FY2024 net loss $67.9M/$255.9M; SUMMIT results due July 2025","bullets":["Net loss Q4 $67.9M, FY $255.9M (vs $54.4M and $192.4M); R&D spend $62M/$232.7M.","Cash, equivalents and marketable securities $287.1M at 12/31/24 plus $25M from ATM; runway into late 2026.","Top-line SUMMIT (NonAdvSM) results expected July 2025; APEX (AdvSM) enrollment complete, data 2H 2025.","NDA submission for bezuclastinib planned by end-2025; PEAK (GIST) top-line by end-2025.","Preclinical IND for ErbB2 inhibitor CGT4255 and PI3Kα inhibitor CGT6297 planned in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-026103","json":"https://secwatch.observer/filing/0000950170-25-026103.json","markdown":"https://secwatch.observer/filing/0000950170-25-026103.md","text":"https://secwatch.observer/filing/0000950170-25-026103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000095017025026103/0000950170-25-026103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000095017025026103/cogt-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:46:44.932184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}